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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYFragile X syndrome (FXS) is themost commonheritable formof cognitive impairment. It results from epigenetic silencing of the X-linked
FMR1 gene by a CGG expansion in its 50-untranslated region. Taking advantage of a large set of FXS-affected human embryonic stem cell
(HESC) lines and isogenic subclones derived from them, we show that FMR1hypermethylation commonly occurs in the undifferentiated
state (six of nine lines, ranging from 24% to 65%). In addition, we demonstrate that hypermethylation is tightly linked with FMR1 tran-
scriptional inactivation in undifferentiated cells, coincides with loss of H3K4me2 and gain of H3K9me3, and is unrelated to CTCF bind-
ing. Taken together, these results demonstrate that FMR1 epigenetic gene silencing takes place in FXS HESCs and clearly highlights the
importance of examining multiple cell lines when investigating FXS and most likely other epigenetically regulated diseases.INTRODUCTION
Fragile X syndrome (FXS;OMIM#300624) is themost com-
mon heritable form of cognitive impairment. It is inherited
as an X-linked trait and is caused by a deficiency in the frag-
ile X mental retardation protein (FMRP) (Santoro et al.,
2012). Most patients lack FMRP due to an unstable expan-
sion of a CGG trinucleotide repeat sequence in the 50-un-
translated region of the FMR1 gene (Kremer et al., 1991;
Oberle´ et al., 1991; Verkerk et al., 1991; Yu et al., 1991).
The number of CGG repeats varies so that normal individ-
uals carry 5 to 55 repeat copies, while affected patients carry
over 200 copies (full mutation). Expansion of repeat copy
number to over 200 CGGs (Nolin et al., 1996) coincides
with local acquirement of abnormal DNA methylation
and the gain of repressive histone modifications typical
to densely packed chromatin (like H3K9 and H3K27 trime-
thylation) (Coffee et al., 1999, 2002; Kumari and Usdin,
2010; Oberle´ et al., 1991; Pietrobono et al., 2005; Tabolacci
et al., 2005, 2008). These epigenetic modifications, which
are presumed to be acquired in a developmentally regu-
lated process, are responsible for FMRP deficiency and dis-
easemanifestation through transcriptional silencing of the
FMR1 gene in affected fetuses as early as 6–13 weeks of age
(Devys et al., 1992; Sutcliffe et al., 1992; Suzumori et al.,
1993).
Formerly, we established a human embryonic stem cell
(HESC) line from a fragile X-affected embryo, which was
obtained through a preimplantation genetic diagnosticStem Cell R(PGD) procedure (Eiges et al., 2007). This cell line, termed
HEFX, transcribes FMR1 mRNA levels that are comparable
to the levels in wild-type (WT) HESCs. In addition, it is
completely unmethylated, despite the presence of a full
expansion. These findings have led us to propose that
epigenetic gene silencing is conditioned by differentiation
and that DNA methylation is a relatively late event in the
silencing process. To further substantiate the notion that
FMR1 is transcriptionally active in the undifferentiated
state, we derived and fully characterized eight additional
HESC lines established from fragile X-affected embryos.
These and the former cell line were used to better define
the timing and nature of FMR1 epigenetic gene silencing
during early embryo development.RESULTS
FXS HESC Line Derivation
Twelve different mutant HESC lines were established from
embryos with a CGG expansion greater than 55 repeats at
the FMR1 gene (Table 1). The embryos, which were ob-
tained through PGD,were donated by seven unrelated cou-
ples in which the mothers had a premutation at the FMR1
gene. All newly established cell lines display key features of
pluripotent cells, namely unrestricted growth in culture,
expression of undifferentiated cell-specific markers, and
the potential to differentiate into a wide range of cell types
(Figure S1 available online).eports j Vol. 3 j 699–706 j November 11, 2014 j ª2014 The Authors 699
Table 1. FXS HESC Line Collection
HESC Line Sex Expansion Size Family
Maternal Expansion
Size
SZ-FX1 XX FM B 75
SZ-FX3 XX FM A 100–300
SZ-FX4 XY PM B 75
SZ-FX5 XX PM B 75
SZ-FX6 XY FM C 170
SZ-FX7 XX FM (mosaic) B 75
SZ-FX8 XY FM D 80
LS-FX9a XY FM (mosaic) G NA
SZ-FX10 XX PM B 75
SZ-FX12 XX FM (mosaic) B 75
SZ-FX14 XY FM E 75
HEFXb XY FM F NA
Twelve different HESC lines were established from embryos with a CGG
expansion in the FMR1 gene. The embryos, which were obtained through
PGD, were donated by seven unrelated couples in which the mothers had
a premutation at the FMR1 gene. Of the 12 available cell lines, 9 (including
the former HEFX cell line) were found to carry a CGG expansion greater than
200 repeats. FM, full mutation (>200 repeats); NA, not available; PM, premu-
tation (55–200 repeats).
aKindly provided by Racine IVF Unit, Tel Aviv Sourasky Medical Center.
bEiges et al. (2007).
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To determine the number of CGG repeats in each cell line
and to generally assess the methylation state of FMR1 at
the promoter, we employed a commonly used methyl-
ation-sensitive Southern blot assay that relies on DNA re-
striction with a methylation-sensitive enzyme (Rousseau
et al., 1991). Employing this potent test has facilitated
the identification of full mutations (>200 CGGs) in eight
different cell lines: four females and four males, three of
which are repeat size mosaics, meaning that they carry
both premutation and full mutation alleles concurrently
(LS-FX9, SZ-FX7, and SZ-FX12) (Figure 1A). All apart from
two cell lines (SZ-FX7 and SZ-FX12) display aberrant
methylation. We roughly estimate the length of the CGG
expansion in the XY FXS HESC lines as 200–650 (HEFX),
200–330 (SZ-FX6), 200–300 (SZ-FX8), and 50–300 (LS-
FX9) repeats when unmethylated, and ranging from 290–
600 repeats when methylated (SZ-FX6, SZ-FX8, LS-FX9,
and SZ-FX14). In a similar way, we estimate expansion
size in XX FXS HESCs as 200–300 (SZ-FX7), 150–300 (SZ-
FX12) when unmethylated, and ranging from 300 to 600
repeats when methylated (SZ-FX1 and SZ-FX3). While full
mutations consistently show a smear of bandswhen unme-700 Stem Cell Reports j Vol. 3 j 699–706 j November 11, 2014 j ª2014 Thethylated, discrete band patterns are observed when expan-
sions are methylated. These results neatly illustrate the
heterogeneous nature of our cell lines.
Given that FMR1 is liable to hypermethylation by X inac-
tivation (Xi) and is polymorphic for CGG repeat number in
all FXS XX HESCs, we can gain additional information
regarding Xi patterns within the XX cells by the Southern
blot test. We find that like many XX HESC lines, Xi has
already occurred in all of the female cell lines (Shen et al.,
2008) and is consistently skewed. The nature of the
skewing, which was validated by a methylation-sensitive
PCR-based assay (Kiedrowski et al., 2011), demonstrates
that in three of four lines the normal X was inactivated
(Figure S2A).
Analysis of CpG Methylation by Bisulfite Sequencing
and Pyrosequencing
To better define abnormal methylation in FXS HESCs and
finely characterize the extent of methylation close to the
repeats, we applied bisulfite pyrosequencing, which relies
on massive parallel sequencing, at regions that were previ-
ously shown by others to be differentially methylated in
patients’ somatic cells (Godler et al., 2010). Methylation
analysis was limited to XY cells, as this assay does not
distinguish between Xi methylation and CGG full-expan-
sion abnormal methylation in XX cells. We find that
methylation levels widely vary among our XY FXS HESC
lines, ranging from 24% (SZ-FX6) to 65% (SZ-FX14) up-
stream and 46%–77% downstream of the CGGs (Fig-
ure 1B). These levels are generally lower than in somatic
cells of patients, which range between 73% and 95% (as
determined by the analysis of primary cultures from five
different individuals; Figure S2B), and are steady over
time in culture, based on the analysis of HEFX and two
other partly methylated FXS HESC lines (SZ-FX6 and
SZ-FX14) (Figure S2C). In addition, we analyzed methyl-
ation levels by bisulfite single colony sequencing to deter-
mine methylation patterns at the resolution of single DNA
molecules. Using this approach, we find a complete di-
chotomy of hypomethylated and hypermethylated alleles,
reflecting two distinct FMR1 active and inactive states
(Figure S2D).
Analysis of Histone Modifications and CTCF Binding
in XY FXS HESCs by Chromatin Immunoprecipitation
Analysis
To further substantiate the notion of epigenetic silencing
being frequently elicited prior to differentiation, two his-
tone modifications were examined in three of our XY
FXS HESCs representing low (<5%, HEFX), intermediate
(40%–48%, LS-FX9), and high (65%–76%, SZ-FX14)
methylation states, by chromatin immunoprecipitation
(ChIP). We show that methylation levels strongly correlateAuthors
AB
Figure 1. CGG Expansion Size and Methylation State in FXS HESC Lines
(A) CGG expansion size and methylation state were determined by a methylation-sensitive Southern blot assay. This test distinguishes
between unmethylated normal (2.8 kb), premutation (2.9–3.4 kb), and full-mutation alleles (3.4–5.8 kb) and their methylated equiva-
lents, as indicated by 5.2 kb, 5.3–5.8 kb, and fragments larger than 5.8 kb, respectively. Full mutations were identified in nine different
cell lines (including HEFX): four females and five males. Note that SZ-FX7, SZ-FX12 and LS-FX9 are mosaic for the full mutation (carry both
full and premutations) and that most cell lines are aberrantly methylated (SZ-FX1,3,6,8,14 and LS-FX9). Xi patterns are observed within XX
FXS cells.
(B) Schematic illustration of the regions analyzed next to the repeats (top) and the bisulfite pyrosequencing results for DNA methylation
levels at CpG sites localized 50 (16 CpGs) and 30 (6 CpGs) to the CGGs (bottom).
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FMR1 Epigenetic Silencing in FXS HESCswith local gain of repressive (H3K9me3) and loss of active
(H3K4me2) histone modifications (Figure 2A). At the
same time, to explore a potential mechanistic link between
hypermethylation and CTCF binding, we examined
whether methylation is associated with the binding loss
of CTCF protein next to the repeats, as formerly suggested
(Ladd et al., 2007). For this purpose, we assessed CTCF
enrichment along the 50 end of FMR1 in four different
HESC lines by ChIP analysis. However, no enrichment for
CTCF could be detected in both WT and affected HESCs
(Figure 2D).Stem Cell RFMR1 Expression in FXS HESCs
To explore whether FMR1 is transcriptionally active in FXS
HESCs, real-time RT-PCR was carried out in both XX and
XY FXS and control (WT) HESC lines (Figure 2B). For
each cell line, the level of transcription was determined
by the analysis of at least two unrelated cell cultures. Based
on quantitative RT-PCR (qRT-PCR) analysis, we show that
FMR1 expression in HEFX cells (0% methylation) is indis-
tinguishable from WT HESCs and is equally reduced in
partly methylated FXS cell lines (t test for unequal vari-
ances, p % 0.01). This is in contrast to SZ-FX4, a XYeports j Vol. 3 j 699–706 j November 11, 2014 j ª2014 The Authors 701
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Figure 2. Histone Modifications, FMR1
Expression and CTCF Binding in FXS
HESCs
(A) Real-time PCR ChIP analysis for
H3K9me3 and H3K4me2 in WT and FXS-
affected HESCs. APRT and HOXA9 were
used as negative and positive controls for
H3K9me3, respectively, while CRYSTALIN
and APRT were used as negative and positive
controls for H3K4me2, respectively (both
positive controls were set to one and are not
presented). The data in each panel repre-
sents an average of three to five indepen-
dent ChIP experiments. Error bars represent
standard error (paired t test, *p < 0.05,
**p < 0.01, ***p < 0.001).
(B) Mean real-time RT-PCR analysis of FMR1
transcription in XY (left) and XX (right) WT,
FXS affected, and premutation (SZ-FX4)
HESC lines. The expression level of each cell
line represents an average of three to seven
independent experiments. Cycle threshold
(Ct) values were normalized to the corre-
sponding Ct value of GAPDH. XY WT cell lines
are B200, and the XX WT cell line is B123.
Error bars represent standard error (t test for
unequal variances, *p < 0.05, **p < 0.01,
***p < 0.001).
(C) Western blot analysis of FXS HESCs
confirming the expressions of FMRP (72
kD) in WT and XY FXS HESCs. GAPDH (40 kD)
was used as a loading control.
(D) ChIP analysis of CTCF relative enrichment along the FMR1 locus (300 to +10 Kb relative to the transcription start site) in WT and FXS-
affected HESCs. APRT was used as a negative control, and the average of DMPK (DM1) and FRATAXIN (FXN) genes was used as a positive
control (the average of positive controls was set to one). The data in each panel represent an average of three independent ChIP
experiments. Error bars represent standard error.
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FMR1 Epigenetic Silencing in FXS HESCspremutation cell line that exhibits a marked increase in
FMR1 levels as observed in premutation carriers (Tassone
et al., 2001). FMR1 transcript levels largely correlate with
the extent of FMRP expression, as determined by western
blot analysis (Figure 2C). This is true for all examined XY
cell lines apart from LS-FX9, which demonstrates marked
increase in FMRP, as compared with WT control (two bio-
logical replicas), despite reduced FMR1mRNA levels.
Comparison of Histone Modifications and mRNA
Levels between Isogenic Hypermethylated versus
Hypomethylated FXS HESC Lines
To better establish the relationship between epigenetic
modifications and gene expression at the cellular level,
we subcloned undifferentiated SZ-FX6 and SZ-FX14 cells.
Single-cell colonies were manually isolated following
transfection with a GFP-NEO-resistant gene under the
continuous selection of G418. We first screened for FMR1
expression by real-time RT-PCR (Figure 3A) to distinguish702 Stem Cell Reports j Vol. 3 j 699–706 j November 11, 2014 j ª2014 Thebetween FXS HESC clones that are entirely unmethy-
lated/methylated. FMR1-expressing/nonexpressing clones
were verified for methylation state by bisulfite pyrose-
quencing (Figure 3B). Indeed, FMR1-expressing clones
were consistently unmethylated, while FMR1-nonexpress-
ing clones were at all times heavily methylated. Full
mutations were validated in all clones by Southern blot
and/or PCR analysis (data not shown). In addition, we
compared the enrichments of H3K4me2 and H3K9me3
between SZ-FX6 hypermethylated (SZ-FX6 cl.15B) and
hypomethylated (SZ-FX6 cl.12B) clones and found a
strong correlation between hypermethylation and exten-
sive loss of H3K4me2, coinciding with the acquisition of
H3K9me3 (Figure 3C), and vice versa for hypomethylated
expansions. Taken together, based on the analysis of
FXS HESC clones, we show that aberrant methylation is
tightly linked with transcriptional silencing of FMR1 and
cannot be separated from the change in histone modifica-
tions in HESCs.Authors
AB
C
Figure 3. FMR1 Transcription, Methyl-
ation Levels and Histone Modifications
in Subclones of FXS HESCs
(A) Mean relative FMR1 transcription levels
of subclones from SZ-FX6 (left) and SZ-FX14
(right). Two independent qRT-PCR experi-
ments were performed on a single passage
culture. Ct values were normalized to the
corresponding Ct value of GAPDH. Error bars
represent standard error.
(B) Bisufite pyrosequencing for methylation
levels near the CGGs (50 left and 30 right) in
several of FXS HESC (SZ-FX6 and SZ-FX14)
subclones.
(C) Real-time PCR ChIP analysis of H3K9me3
and H3K4me2 immediately upstream to the
CGGs, in hypomethylated (SZ-FX6 cl.12B)
versus hypermethylated (SZ-FX6 cl.15B)
isogenic subclones. APRT and CRYSTALIN
were used as negative controls for H3K9me3
and H3K4me2, respectively. The data in
each panel represent an average of three to
five independent ChIP experiments (paired
t test, **p < 0.01, ***p < 0.001). Error bars
represent standard error.
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Here we report on altogether nine different HESC lines
bearing pathologic expansions larger than 200 copies at
the FMR1 gene. This collection of undifferentiated FXS
cells, which is the largest to the best of our knowledge,
comprises five male and four female cell lines. Taking
advantage of this set of HESCs, we showhere that FMR1hy-
permethylation is frequently present in FXS HESCs (six of
nine lines), ranging from 24% to 65% in the FMR1 pro-
moter, unlike what was previously described. The inconsis-
tency between this and former studies regarding the timing
by which FMR1 is initially methylated stems from the
different cell types/cell lines employed. While we focus
on cell lines that are equivalent to the inner cell mass
(ICM) of embryos prior to implantation, most other studies
relied on the analysis of FMR1 epigenetic gene silencing in
chorion villi of FXS fetuses, which often does not reflect
that of embryonic tissues (Sutherland et al., 1991; Sutcliffe
et al., 1992; Castellvı´-Bel et al., 1995). In addition, formerly
we examined only one XY FXS HESC line (HEFX; EigesStem Cell Ret al., 2007), while here we extended this study and charac-
terized eight additional XX and XY cell lines.
We demonstrate that the CGG expansions are either
completely methylated or entirely hypomethylated, re-
flecting two distinct epigenetic states. Methylation levels
remain unchanged over time in culture and are tightly
coupled with a change in histone modifications: loss in
H3K4me2 (active mark) and gain in H3K9me3 (repressive
mark). This cannot be attributed to failed CTCF binding
at the FMR1 locus, as previously proposed, since no enrich-
ment for CTCFwas found in FMR1 in bothWTand affected
HESCs. These results are different from the reports by Ladd
et al. (2007) and Lanni et al., (2013) andmay stem from the
different cell types employed.
Regarding FMR1 transcription by FXS HESCs, we show
that FMR1 expression in unmethylated FXS HESCs
(HEFX, 0% methylation) is indistinguishable from WT
HESCs and is significantly reduced in all methylated FXS
cell lines. Nevertheless, the relation between the extent of
methylation and FMR1 expression levels is not a simple
correlation, as all methylated cell lines express FMR1 ateports j Vol. 3 j 699–706 j November 11, 2014 j ª2014 The Authors 703
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FMR1 Epigenetic Silencing in FXS HESCssimilar levels. FMR1 transcription levels often (but not
always) reflect FMRP expression. To better establish the
association between methylation and FMR1 transcription,
we compared undifferentiated isogenic clones that are hy-
permethylated versus hypomethylated expansions. While
all of the unmethylated clones expressed FMR1, theirmeth-
ylated counterparts were completely deficient of FMR1
mRNA. These results further substantiate the relevance of
DNA methylation to the silencing process in undifferenti-
ated FXSHESCs. In addition, by comparing the enrichment
of H3K4me2 andH3K9me3 between isogenic hypermethy-
lated/hypomethylated clones, we show that aberrant his-
tone modifications are at all times coupled and cannot be
separated from DNA hypermethylation in HESCs.
Previous studies involving FXS HESCs, including some of
our cell lines, point to the role of cell differentiation in the
silencing of the FMR1 gene (Telias et al., 2013). In line with
this view is the recent report of Colak and colleagues, who
employed two FXS HESC lines to uncover an mRNA-medi-
atedmechanism that drives epigenetic gene inactivation in
a way that relies on neuronal differentiation (Colak et al.,
2014). It remains to be determined whether this mecha-
nism can act also at earlier developmental stages or if
silencing is achieved in undifferentiated cells by a distinct
mechanism. Furthermore, it also remains to be determined
whether the loss of FMR1 mRNA and FMRP protein in the
FXS HESC-derived neurons involves hypermethylation.
Our FXS HESCs widely vary in methylation levels
(0%–65%, upstream to the CGGs by pyrosequencing). We
show at the resolution of individual DNA molecules by
bisulfite single colony sequencing that the methylation
states of full mutations are binary, either completely meth-
ylated or entirely unmethylated. As FMR1 methylation
levels remain unchanged over time in culture, it seems
that unmethylated full expansions most likely arise due
to imperfect de novo methylation rather than from an
inability to reproducibly maintain aberrant methylation
patterns. This may suggest that not all the cells in the
ICM are evenly FMR1 methylated before or at the time of
cell line derivation. We argue that the wide variability in
methylation levels among the cell lines reflects a wide-
spread event within mutant FMR1 embryos.
The failure to methylate expansions greater than 200
CGGs may point to a ‘‘window of opportunity’’ within
which aberrant methylation can occur so that expansions
that have coincidentally escaped de novo methylation
persist. We propose a model that relates to the timing and
nature of FMR1 hypermethylation, which suggests that
abnormal methylation is first gained on full expansions
in FXS at a restricted time point before/during blastocyst
formation. Once established, it is irreversible and is clon-
ally maintained. Expansions that fail to acquire abnormal
methylation during this limited time frame remain unme-704 Stem Cell Reports j Vol. 3 j 699–706 j November 11, 2014 j ª2014 Thethylated and under various differentiation conditions
become silenced. In line with this model is the existence
of methylation mosaicism among affected individuals
(which is not that uncommon), the majority of whom ex-
press significant levels of FMR1 mRNA (Tassone et al.,
2001). In addition, the proposed model also provides an
appropriate explanation for the independent results of
Urbach and Sheridan, who demonstrate that FMR1 hyper-
methylation, once established, is irreversible and cannot be
erased by cell reprogramming through the formation of
FXS-iPS cells (Sheridan et al., 2011; Urbach et al., 2010).
In line with this perception, it should be feasible to obtain
FXS-iPS clones that are FMR1 active from somatic cells with
a full mutation provided that they carry an unmethylated
full expansion at least in some of their cells. Indeed, we suc-
cessfully established a fully reprogrammed (Figures S3A–
S3D) and FMR1-active iPS clone with an unmethylated
full mutation from patient fibroblasts with intermediate
methylation levels (77%) (Figures S3E–S3G).
To summarize, this study demonstrates that FMR1 epige-
netic gene silencing can take place in undifferentiated FXS
cells and underscores the importance of examining multi-
ple cell lines when investigating epigenetically regulated
disorders.EXPERIMENTAL PROCEDURES
HESC Line Derivation
All cell lines were established in Shaare Zedek Medical Center
(Institutional Review Board [IRB] 87/07) apart from LS-FX9, which
was kindly provided by the Racine IVF Unit, Tel-Aviv Sourasky
Medical Center (IRB 7/04-043). Cell line derivation and character-
ization were carried out as previously described (Eiges et al., 2007).RT-PCR
Total RNA was isolated from the cells by TRI reagent extraction.
RNA (1 mg) was reverse transcribed (Multi Scribe RT, ABI) with
random hexamer primers. Real-time PCR was performed using
Power SYBR Green Master Mix (ABI) on an ABI 7900HT instru-
ment. Primers are listed in Table S1.Western Blot Analysis
Cell pelletswere collected inRIPA buffer (50mMTrisHCl, 0.1%SDS,
0.5%NaDeoxycholate, 1%NP40, 150mMNaCl, 1mMphenylme-
thanesulfonylfluoride, and complete protease inhibitor [Roche]).
Resulting lysates were then electrophoretically resolved and trans-
ferred onto a polyvinylidene fluoride membrane. Following block-
ing with 1% skim milk in Tris-buffered saline with Tween 20
(TBST), the membrane was probed either with a rabbit polyclonal
antibody against FMRP (Abcam, ab17722, 1:1,000 dilution) fol-
lowed by goat anti-rabbit horseradish peroxidase (HRP)-conjugated
antibody (1:5,000 dilution) or with a monoclonal antibody against
GAPDH (Abcam, ab8245 1:2,000) followed by rabbit anti-mouse
HRP-conjugated antibody (1:50,000). Detection was carried outAuthors
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the manufacturer’s protocol (Biological Industries).
Southern Blot Analysis
Genomic DNAs (10–25 mg) were digested with EcoRI and EagI
(NEB), separated on 0.8% agarose gels, blotted onto Hybond
N+ membranes (Amersham), and hybridized with a PCR Dig-
labeled probe (primers: 50-GCTAGCAGGGCTGAAGAGAA-30 and
50-CAGTGGAGCTCTCCGAAGTC-30).
Bisulfite Sequencing
Genomic DNA (2 mg) was modified by bisulfite treatment (EZ DNA
Methylation-Direct Kit, Zymo Research) and amplified by FastStart
DNApolymerase (Roche) using primers listed in Table S2. For pyro-
sequencing, additional internal sequencing primers were used as
listed in Table S2. The PCR products were analyzed using PyroMak
Q24 (QIAGEN).
ChIP
ChIPwas performed according to the Upstate EZ ChIP kit protocol.
Immunoprecipitation was performed using an anti-H3K4me2
(Upstate 07-030), anti-H3K9me3 (Abcam 8898), or anti-CTCF
(Upstate 07-729) antibody. Real-time PCR was carried out using
primers listed in Table S3. DDCt values were normalized according
to positive controls.
Transfection of HESCs
Cells were transfected with CMV-EGFP-N1 plasmid using LT1-
TransIT transfection reagent (MIRUS) according to the manufac-
turer’s protocol.
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